Previous 10 | Next 10 |
Shares of Agenus (NASDAQ: AGEN) fell as much as 14.1% today after an update from the pipeline underwhelmed investors. The development-stage biopharmaceutical company announced positive interim data from a combination therapy of balstilimab (AGEN2034) and zalifrelimab (AGEN1884) as a second-l...
SAN CARLOS, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2019 financial results on Tuesday, February 25, 2020. Man...
SAN CARLOS, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following conferences: Guggenheim Health...
Investors can't discount the possibility that the field of cellular medicine is a little overhyped right now, but the potential is huge. Researchers are toiling away at the bench and in the clinic to determine the best cell types to use as a starting point for a therapy, the best ways to engine...
Source: GraycellAdvisors.com Systematic Investing Systematic investing has become a growing part of the stock market. The investing style refers to a rules-based algorithmic system that limits or eliminates individual judgments and biases towards portfolio selection and adjustments. ...
Iovance Biotherapeutics (NASDAQ: IOVA ) announces that the last patient has completed dosing in cohort 4 of its Phase 2 registration-enabling study, C-144-01 , evaluating cell therapy lifileucel (LN-144) in metastatic melanoma patients, a Fast Track, Regenerative Medicine Advanced Therapy...
- Biologics Licensing Application (BLA) submission planned for late 2020 - SAN CARLOS, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the ...
Healthcare companies are gathering in San Francisco this week for the annual JP Morgan Healthcare Conference, a high-profile event that's historically been a great venue for announcing mergers and acquisitions (M&A) and licensing agreements. So far, there haven't been any big M&A deals,...
Iovance Biotherapeutics (NASDAQ: IOVA ) inks an agreement with Novartis (NYSE: NVS ) for the right to develop and commercialize an antibody cytokine-engrafted protein, specifically an engineered IL-2 CDR graft, named IOV-3001. More news on: Iovance Biotherapeutics, Inc., Novartis AG, Hea...
SAN CARLOS, Calif., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...